Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases

Clinical and Experimental Metastasis

Volumn 15, Issue 5, 1997, Pages 499-508

  Santos, Orlando ^a,b   McDermott, Charles D ^a   Daniels, Richard G ^a   Appelt, Krzysztof ^a  

^a AGOURON PHARMACEUTICALS INC   (United States)

^b NONE   (United States)

Author keywords

Cancer; Lewis lung carcinoma; Matrixmetalloproteinases; Metastasis; Pharmacokinetics

Indexed keywords

AG 3287; AG 3293; AG 3294; AG 3296; AG 3319; MATRIX METALLOPROTEINASE INHIBITOR; PRINOMASTAT; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG EFFICACY; ENZYME INHIBITION; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG CARCINOMA; LUNG METASTASIS; MOUSE; NONHUMAN;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CARCINOMA, LEWIS LUNG; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HALF-LIFE; MELANOMA, EXPERIMENTAL; METALLOENDOPEPTIDASES; MICE; ORGANIC CHEMICALS; RATS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0030816454     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018418725453     Document Type: Article

References (66)

1. Baramova E and Foidart J-M, 1995, Matrix metalloproteinase family. Cell Biol In, 19, 239-42.
2. Basset P, Bellocq JP, Wolf C, et al. 1990, A novel metalloproteinase gene expressed in stromal cells of breast carcinoma. Nature, 348, 699-704.
3. Birkedal-Hansen H, Moore WGI, Bodden MK, et al. 1993, Matrix metalloproteinases: a review. Crit Rev Oral Biol Med, 4, 197-250.
4. Davies M and Lovett DH, 1995, Metalloproteinases. Mol Nephrol, 61-9.
5. Emonard H and Grimaud J-A, 1990, Matrix metalloproteinases. A Review. Cell Mol Biol, 36, 131-53.
6. Matrisian LM, 1992, The matrix-degrading metalloproteinases. BioEssays, 14, 455-62.
7. Nagase H, Ogata Y, Suzuki K, Enghild J and Salvesen G, 1991, Substrate specificities and activation mechanisms of matrix metalloproteinases. Biochem Soc Trans, 19, 715-18.
8. Nagase H, Barrett AJ and Woessner JF, 1992, Nomenclature and glossary of the matrix metalloproteinases. In: Birkedal-Hansen H, Werb Z, Welgus HG, and Van Wart HE, eds. Matrix Metalloproteinases and Inhibitors. Proceedings of the Matrix Metalloproteinase Conference, Sandestin Beach, Florida, September 11-15. New York: Gustav Fischer Verlag.
9. Wilson CL and Matrisian LM, 1996, Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. Int J Biochem Cell Biol, 28, 123-36.
10. Corcoran ML, Kleiner DE Jr and Stetler-Stevenson WG, 1995, Regulation of matrix metalloproteinases during extracellular matrix turnover. Adv Exp Med Biol, 385, 151-9.
11. Crawford HC and Matrisian LM, 1994, Tumor and stromal expression of matrix metalloproteinases and their role in tumor progession. Invasion Metastasis, 14, 234-45.
12. Fidler IJ and Radinsky R, 1990, Genetic control of cancer metastasis. J Natl Cancer Inst, 82, 166-8.
13. Liotta LA, Steeg PS and Stetler-Stevenson WG, 1991, Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64, 327-36.
14. MacDougall JR and Matrisian LM, 1995, Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev, 14, 351-62.
15. Matrisian LM, Wright J, Newell K and Witty JP, 1994, Matrix-degrading metalloproteinases in tumor progression. Proc Int Symp Princess Takamatsu Cancer Res Fund, 24, 152-61.
16. Mignatti P and Rifkin DB, 1993, Biology and biochemistry of proteinases in tumor invasion. Physiol Rev, 73, 161-95.
17. Mullins DE and Rohrlich ST, 1983, The role of proteinases in cellular invasiveness. Biochim Biophys Acta, 695, 177-214.
18. Ray JM and Stetler-Stevenson WG, 1996, Matrix metalloproteinases and malignant disease: recent developments. Expert Opin Invest Drugs, 5, 323-35.
19. Stetler-Stevenson WG, Liotta LA and Kleiner DE Jr, 1993, Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J, 7, 1434-41.
20. Woessner JF Jr, 1991, Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J, 5, 2145-54.
21. Bonfill RD, Reddel RR, Ura H, et al. 1989, Invasive and mestastatic potential of a v-Ha-ras-transformed human bronchial epithelial cell line. J Natl Cancer Inst, 81, 587-94.
22. Koop S, Khokha R, Schmidt EE, et al. 1994, Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res, 54, 4791-7.
23. Montgomery AMP, Mueller BM, Reisfeld RA, Taylor SM and DeClerck YA, 1994, Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res, 54, 5467-73.
24. Powell WC, Knox JD, Navre M, et al. 1993, Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. Cancer Res, 53, 417-22.
25. Sreenath T, Matrisian LM, Stetler-Stevenson W, Gattoni-Celli S and Pozzatti RO, 1992, Expression of matrix metalloproteinase genes in transformed rat cell lines of high and low metastatic potential. Cancer Res, 52, 4942-7.
26. Witty JP, McDonnell S, Newell KJ, et al. 1994, Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo. Cancer Res, 52, 4805-12.
27. Basset P, Bellocq JP, Wolf C, et al. 1990, A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinoma. Nature, 348, 699-704.
28. Brown PD, Bloxidge RE, Stuart NSA, Gatter KC and Carmichael J, 1993, Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst, 85, 574-8.
29. Campo E, Merino MJ, Tavassoli FA, Charonis AS, Stetler-Stevenson WG and Liotta LA, 1992, Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumors of the ovary. Am J Surg Pathol, 16, 500-7.
30. Gress TM, Mueller-Pillasch F, Lerch MM, Friess H, Buechler M, and Adler G, 1995, Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer, 62, 407-13.
31. Liabakk N-B, Talbot I, Smith RA, Wilkinson K and Balkwill F, 1996, Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res, 56, 190-6.
32. McDonnell S, Navre M, Coffey RJ Jr and Matrisian LM, 1991, Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas. Mol Carcinog, 4, 527-33.
33. Muller D, Wolf C, Abecassis J, et al. 1993, Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas. Cancer Res, 53, 165-9.
34. Murray GI, Duncan ME, O'Neil P, Melvin WT and Fothergill JE, 1996, Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med (NY), 2, 461-2.
35. Nuovo GJ, MacConnell PB, Simsir A, Valea F and French DL, 1995, Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res, 55, 267-75.
36. Pajouh MS, Nagle RB, Breathnach R, Finch JS, Brawer MK and Bowden GT, 1991, Expression of metalloproteinase genes in human prostate cancer. J Cancer Res Clin Oncol, 117, 144-50.
37. Stearns ME and Wang M, 1993, Type IV collagenase (Mr 72,000) expression in human prostate: benign and malignant tissue. Cancer Res, 53, 878-83.
38. Yamamoto M, Mohanam S, Sawaya R, et al. 1996, Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro. Cancer Res, 56, 384-92.
39. Chirivi RGS, Garofalo A, Crimmin MJ, et al. 1994, Inhibition of the metastatic spread and growth of B16BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer, 58, 460-4.
40. Davies B, Brown PD, East N, Crimmin MJ and Balkwill FR, 1993, A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res, 53, 2087-91.
41. DeClerck YA, Perez N, Shimada H, Boone TC, Langley KE and Taylor SM, 1992, Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res, 52, 701-8.
42. Eccles SA, Box GM, Court WJ, Bone EA, Thomas W and Brown PD, 1996, Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res, 56, 2815-22.
43. Khokha R, 1994, Suppression of tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of metalloproteinase-1. J Natl Cancer Inst, 86, 299-304.
44. Naito K, Kanbayashi N, Nakajima S, et al. 1994, Inhibition of growth of human tumor cells in nude mice by a metalloproteinase inhibitor. Int J Cancer, 58, 730-5.
45. Okuyama A, Naito K, Morishima H, Suda H, Nishimura S and Tanaka N, 1994, Inhibition of growth of human tumor cells in nude mice by a metalloproteinase inhibitor. Ann NY Acad Sci, 732, 408-10.
46. Reich R, Thompson EW and Iwamoto Y, 1988, Effects of inhibitors of plasminogen activator, serine proteases and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res, 48, 3307-12.
47. Schultz RM, Silberman S, Persky B, Bajkowski AS and Carmichael DF, 1988, Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16F10 melanoma cells. Cancer Res, 48, 5539-45.
48. Sledge GW Jr, Oulali M, Goulet R, Bone EA and Fife R, 1995, Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst, 87, 1546-50.
49. Taraboletti G, Garofalo A, Belotti D, et al. 1995, Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst, 87, 293-8.
50. Wang X, Fu X, Brown PD, Crimmin MJ and Hoffman RM, 1994, Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res, 54, 4726-8.
51. Watson SA, Morris TM, Robinson G, Crimmin MJ, Brown PD and Hardcastle JD, 1995, Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res, 55, 3629-33.
52. Beattie GJ, Young HA and Smyth JF, 1994, Phase I study of intra-peritoneal metallo-proteinase inhibitor BB94 in patients with malignant ascites. 7th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands.
53. Brown PD, 1995, Matrix metalloproteinase inhibitors: a novel class of anticancer agents. Adv Enzyme Regul, 35, 293-301.
54. O'Byrne KJ, Macaulay VM, Long L, et al. 1996, Phase I study of matrix metalloproteinase (MMP) inhibitor batimastat (BB94) in patients (pts) with malignant pleural effusions. 9th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands.
55. Brown PD, 1996, Synthetic matrix metalloproteinase inhibitors: from cancer models to cancer patients. Proceedings of the 87th Annual Meeting of the American Association for Cancer Research, Washington, DC.
56. Eisenberger MA and Nelson WG, 1996, How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution! J Natl Cancer Inst, 88, 779-81.
57. Thalmann GN, Sikes RA, Chang S-M, Johnston DA, Von Eschenbach AC and Chung LWK, 1996, Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. J Natl Cancer Inst, 88, 794-801.
58. Fidler IJ, 1973, Selection of successive tumor lines for metastasis. Nature, 242, 148-9.
59. Sugiura K and Stock CC, 1955, The effect of phosphoromides on the growth of a variety of mouse and rat tumors. Cancer Res, 15, 38-50.
60. Sokal RR and Rohlf FJ, 1981, Biometry. The Principles and Practice of Statistics in Biological Research, 2nd edn. San Francisco: W. H. Freeman and Company.
61. Bellamy WT, 1992, Prediction of response to drug therapy of cancer. Drugs, 44, 690-708.
62. Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitchell JB, 1987, Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res, 47, 936-42.
63. Goetzl EJ, Banda MJ, and Leppert D, 1996, Matrix metalloproteinases in immunity. J Immunol, 156, 1-4.
64. Bennett TA, Lynam EB, Sklar LA and Rogelj S, 1996, Hydroxamate-based metalloprotease inhibitor blocks shedding of L-selectin adhesion molecule from leukocytes. J Immunol, 156, 3093-7.
65. Gearing AJH, Beckett P and Christodoulou M, et al. 1994, Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature, 370, 555-7.
66. McGeehan GM, Becherer JD and Bast RC Jr, et al. 1994, Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor. Nature, 370, 558-61.